Edwin M Posadas1, Ben Davidson, Elise C Kohn. 1. Laboratory of Pathology, National Cancer Institute and NCI/FDA Clinical Proteomics Program Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies amongst American women. Emerging proteomic technologies have promise for early diagnosis and in advancing treatment directions. Application of these technologies has produced new biomarkers, diagnostic approaches, and understanding of disease biology. RECENT FINDINGS: Mass spectral blood and tissue analysis has yielded new putative biomarkers that require further validation and assessment of diagnostic specificity and sensitivity. Protein signature patterns derived from mass spectrometry datastreams have been modeled and are moving into validation. Tissue-based protein analysis has led to identification of tumor and stromal protein and signal activation events in ovarian cancer. Clinical trials are now ascertaining tissue samples prior to and during therapy with molecularly targeted agents to evaluate modulation of targeted signaling pathways. Finally, proteomic analysis of tissues and metastases will outline biochemical events underlying the metastatic phenotype of ovarian cancer. SUMMARY: Proteomic approaches are experimental technologies applied to ovarian and other cancers. Proper validation and use of findings may advance our understanding of biochemical events that have complicated successful detection and intervention. This knowledge is the first step in fulfilling the promise of personalized molecular medicine.
PURPOSE OF REVIEW: Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies amongst American women. Emerging proteomic technologies have promise for early diagnosis and in advancing treatment directions. Application of these technologies has produced new biomarkers, diagnostic approaches, and understanding of disease biology. RECENT FINDINGS: Mass spectral blood and tissue analysis has yielded new putative biomarkers that require further validation and assessment of diagnostic specificity and sensitivity. Protein signature patterns derived from mass spectrometry datastreams have been modeled and are moving into validation. Tissue-based protein analysis has led to identification of tumor and stromal protein and signal activation events in ovarian cancer. Clinical trials are now ascertaining tissue samples prior to and during therapy with molecularly targeted agents to evaluate modulation of targeted signaling pathways. Finally, proteomic analysis of tissues and metastases will outline biochemical events underlying the metastatic phenotype of ovarian cancer. SUMMARY: Proteomic approaches are experimental technologies applied to ovarian and other cancers. Proper validation and use of findings may advance our understanding of biochemical events that have complicated successful detection and intervention. This knowledge is the first step in fulfilling the promise of personalized molecular medicine.
Authors: S Shanmughapriya; G Senthilkumar; K Vinodhini; B C Das; N Vasanthi; K Natarajaseenivasan Journal: Eur J Clin Microbiol Infect Dis Date: 2012-03-09 Impact factor: 3.267
Authors: Brenda K Weis; David Balshaw; John R Barr; David Brown; Mark Ellisman; Paul Lioy; Gilbert Omenn; John D Potter; Martyn T Smith; Lydia Sohn; William A Suk; Susan Sumner; James Swenberg; David R Walt; Simon Watkins; Claudia Thompson; Samuel H Wilson Journal: Environ Health Perspect Date: 2005-07 Impact factor: 9.031